Go to content
Pharming Group N.V.

Pharming Group N.V.

Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.

Publicatie datum 28 jun 2007 - 12:48
Statutaire naam Pharming Group N.V.
Titel Pharming Provides Portfolio And Technology Update At Company Meeting
Bericht Leiden, The Netherlands, June 28, 2007. Biotech company Pharming Group NV (“Pharming” or “the Company”) (Euronext: PHARM) will present an update of its portfolio of products and technologies during a meeting for analysts and specialized reporters today commencing at 1:30 pm CET. Dr. Jan Hoeijmakers, member of Pharming’s Scientific Advisory Board and professor at the Erasmus Medical Center in Rotterdam, will provide an overview of the current state of the art in the field of DNA-damage and repair. In particular, the link between DNA-damage and ageing will be highlighted. Recent scientific results and their impact on developing therapies for ageing diseases will be discussed. Dr. Frank Pieper, Chief Science and Technology Officer, one of the driving forces behind the development of Pharming’s transgenic technology, will discuss the science behind the production of proteins in milk. Dr. Bruno Giannetti, Chief Operations Officer, will present an update on the development of the various products in Pharming’s portfolio. With respect to Rhucin®, Pharming’s lead product developed as a treatment for heredetary angioedema (“HAE”), Dr. Giannetti will review the clinical program and summarize the relevant data generated so far. He will confirm that the product appears to be safe, well-tolerated and provides rapid relief to patients suffering from acute HAE attacks. He will also discuss the scientific and clinical rationale in developing the product for other indications, in particular for transplantation. With respect to Pharming’s lactoferrin product, Dr. Giannetti will confirm that the product has an excellent safety profile with no significant toxicity observed so far after considerable testing. In very recent interactions with the US-FDA, who are reviewing the dossier in relation to Pharming’s request to obtain GRAS (“Generally Recognized As Safe”) status, it appears that there are no further questions outstanding, and that the FDA will communicate on possible next step